secwatch.observer — SEC 8-K summary
======================================

Issuer:     SeaStar Medical Holding Corp (ICU)
CIK:        0001831868
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0001831868-25-000006
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SeaStar Medical Q2 net loss $2.0M; NEUTRALIZE-AKI trial over 60% enrolled
-------------------------------------------------------------------------

- Net revenue $0.3M from QUELIMMUNE sales; net loss $2.0M ($0.18/share) vs $3.2M loss year ago.
- NEUTRALIZE-AKI trial enrolled 125 of 200 patients; interim DSMB recommendations expected Q3 2025.
- Three new children's hospitals adopted QUELIMMUNE; SAVE registry shows 75% 28-day survival in 20 pediatric patients.
- Raised $12.4M in June and $8.4M in two July/August 2025 offerings; cash at June 30 was $6.3M.
- CMS agreed to cover clinical trial expenses for NEUTRALIZE-CRS; DoD awarded $2M grant for burn research.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831868/000183186825000006/0001831868-25-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831868/000183186825000006/icu-20250813.htm
  HTML page:      https://secwatch.observer/filing/0001831868-25-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer